OSCC cellular response and cIAP1 loss
Cell-based study · Human OSCC panel: HSC-3, HN6, HSC-2, CAL-33, SCC-172, SCC-131, SCC-9, SCC-4 and CAL-27; cIAP response blots in HSC-3, HN6, CAL-33 and SCC-9. [1]
A single-agent response profile combined viability, apoptosis and cIAP immunoblot assays. HSC-3 and HN6 were sensitive, whereas the other seven lines were comparatively resistant. cIAP1 loss occurred in both response classes and cIAP2 remained low and largely unchanged in the tested blots; cIAP1 loss alone therefore did not predict cell killing.
| Endpoint | Reported result | Reference |
|---|---|---|
| Cell viability relative to untreated control | CCK-8 HSC-3 and HN6 were sensitive; HSC-2, CAL-33, SCC-172, SCC-131, SCC-9, SCC-4 and CAL-27 were comparatively resistant at 0.5 or 1 μM for 24 h. No exact viability percentages extracted. | [1] |
| Annexin V/PI apoptosis profile | Flow cytometry LCL161 increased early and late apoptotic fractions in HSC-3; CAL-33 showed little response after 24 h. | [1] |
| cIAP1 and cIAP2 protein abundance | Western blot 1 μM, 24 h: cIAP1 decreased in HSC-3, HN6, CAL-33 and SCC-9; cIAP2 remained low and unaltered. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 or 1 μM for viability/apoptosis; 1 μM for immunoblotting.
- Exposure duration
- 24 h
- Method
- Single-agent cell exposure; untreated controls. No exogenous TNF in these selected assays.
- Reported limits
- Cellular LCL161 solvent/vehicle is not specified in the selected methods. Exact panel-specific n is not specified in the captions.
Methods and source locations
Compound reported in the paper: LCL161; Compound label in the paper: LCL161
Results describe the paper’s LCL161 material; supplier and formulation do not establish equivalence of a current Adooq lot.
Figs 3A–H and 4A–C; relevant Results; Methods, Reagents and antibodies, Cell culture, Cell viability assay, Flow cytometry, Western blot, Statistical analysis
Cell viability relative to untreated control: CCK-8 absorbance at 450 nm, control- and blank-normalized; Fig. 3A/B show mean ± SD, ANOVA. Statistical methods state validation by three or more independent experiments; panel-specific replicate number is not given in the caption. — Fig. 3A/B and caption; Results, OSCC tumor cells exhibit differential sensitivity; Methods, Cell viability assay and Statistical analysis
Annexin V/PI apoptosis profile: Annexin V-FITC/PI; representative plots and summary bars for 0, 0.5 and 1 μM. No exact population percentages transcribed from representative plots. — Fig. 3C–F and caption; Methods, Flow cytometry
cIAP1 and cIAP2 protein abundance: LCL161-treated versus untreated cells; GAPDH loading control. Qualitative interpretation of viewed blots, not a biochemical affinity or IC50 assay. — Fig. 4B/C and caption; Results, cIAP1 is degraded upon SM treatment; Methods, Western blot